ORCID Profile
0000-0001-8644-2827
Current Organisations
University of Minnesota
,
Minneapolis VA Health Care System
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Public Library of Science (PLoS)
Date: 15-02-2013
Publisher: Elsevier BV
Date: 12-2016
Publisher: Oxford University Press (OUP)
Date: 25-10-2017
DOI: 10.1093/OFID/OFX228
Abstract: Indoleamine-2,3-dioxygenase (IDO) mediated tryptophan (TRP) depletion has antimicrobial and immuno-regulatory effects. Increased kynurenine (KYN)-to-TRP (KT) ratios, reflecting increased IDO activity, have been associated with poorer outcomes from several infections. We performed a case-control (1:2 age and sex matched) analysis of adults hospitalized with influenza A(H1N1)pdm09 with protocol-defined disease progression (died/transferred to ICU/mechanical ventilation) after enrollment (cases) or survived without progression (controls) over 60 days of follow-up. Conditional logistic regression was used to analyze the relationship between baseline KT ratio and other metabolites and disease progression. We included 32 cases and 64 controls with a median age of 52 years 41% were female, and the median durations of influenza symptoms prior to hospitalization were 8 and 6 days for cases and controls, respectively (P = .04). Median baseline KT ratios were 2-fold higher in cases (0.24 mM/M IQR, 0.13–0.40) than controls (0.12 IQR, 0.09–0.17 P ≤ .001). When ided into tertiles, 59% of cases vs 20% of controls had KT ratios in the highest tertile (0.21–0.84 mM/M). When adjusted for symptom duration, the odds ratio for disease progression for those in the highest vs lowest tertiles of KT ratio was 9.94 (95% CI, 2.25–43.90). High KT ratio was associated with poor outcome in adults hospitalized with influenza A(H1N1)pdm09. The clinical utility of this biomarker in this setting merits further exploration. NCT01056185.
Publisher: Wiley
Date: 25-02-2015
DOI: 10.1111/HIV.12227
Publisher: Mary Ann Liebert Inc
Date: 2022
Publisher: Elsevier BV
Date: 04-2022
Publisher: Elsevier BV
Date: 11-2019
No related grants have been discovered for Ken Kunisaki.